This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Monrad, E. S. Articles by Abelmann, W. H. Search for Related Content PubMed PubMed Citation Articles by Monrad, E. S. Articles by Abelmann, W. H.

Circulation, Vol 73, 1058-1064, Copyright © 1986 by American Heart Association

ARTICLES

Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus

ES Monrad, A Matsumori, JC Murphy, JG Fox, CS Crumpacker and WH Abelmann

To explain the progression from infectious viral myocarditis to congestive cardiomyopathy an infection/immune hypothesis has been proposed stating that the primary viral process incites an excessive or disordered immunologic response against the myocardium. To test whether one form of immunosuppressive therapy might ameliorate this process, we used cyclosporine in a murine preparation of infectious myocarditis (encephalomyocarditis [EMC] virus), which has been shown to result in a congestive cardiomyopathy pathologically similar to that seen in man. Eight-week-old male DBA-2 mice were infected with EMC virus and randomized to a treatment or control group. Cyclosporine (25 mg/kg/day) was administered subcutaneously for 3 weeks, starting (1) at 1 week after infection during viral replication, and (2) at 3 weeks after infection, after the period of active viral replication. In mice treated during viral replication there was a significantly higher mortality rate compared with that of control mice (15/21 vs 9/29, p = .01). There was no evident reduction in myocardial pathology (inflammation, necrosis, or calcification) in the treated compared with the control groups. In mice treated after the period of viral replication, there was no improvement in mortality (8/22 vs 2/19, NS) compared with control. Treated mice showed no reduction in myocardial histopathologic lesions. Furthermore, treated mice had significantly greater heart weight/body weight ratios (1.3 +/- 0.4% vs 1.0 +/- 0.3%, p less than .005), lung weight/body weight ratios (1.1 +/- 0.5% vs 0.8 +/- 0.3%, p less than .05), and liver weight/body weight ratios (6.0 +/- 0.8% vs 5.4 +/- 0.6%, p less than .005) than control mice, suggesting more severe myocardial failure.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				T. Miyamoto, A. Matsumori, M.-W. Hwang, R. Nishio, H. Ito, and S. Sasayama Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1713 - 1718. [Abstract] [Full Text] [PDF]

				C. Kawai From Myocarditis to Cardiomyopathy: Mechanisms of Inflammation and Cell Death : Learning From the Past for the Future Circulation, March 2, 1999; 99(8): 1091 - 1100. [Abstract] [Full Text] [PDF]

				M. P. Reyes, R. Khatib, G. Khatib, K.L. Ho, F. Smith, and R. A. Kloner Prolonged Captopril Therapy in Murine Viral Myocarditis Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(1): 43 - 49. [Abstract] [PDF]

				G. Grassl, C. L. Pummerer, I. Horak, and N. Neu Induction of Autoimmune Myocarditis in Interleukin-2–Deficient Mice Circulation, April 1, 1997; 95(7): 1773 - 1776. [Abstract] [Full Text]

				M. Kodama, S. Zhang, H. Hanawa, M. Saeki, T. Inomata, K. Suzuki, S. Koyama, and A. Shibata Effects of 15-Deoxyspergualin on Experimental Autoimmune Giant Cell Myocarditis of the Rat Circulation, February 15, 1995; 91(4): 1116 - 1122. [Abstract] [Full Text]